Histone Deacetylase Inhibitors Market By Drug Class (Class I, Class II/IV, Pan-HDAC, Isoform-Selective); By Application (Oncology, Neurology & Psychiatry, Inflammatory & Autoimmune Disorders); By Route of Administration (Oral, Injectable); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

1. Introduction and Strategic Context

The Global Histone Deacetylase ( HDAC ) Inhibitors Market is projected to grow at a CAGR of 8.9% , reaching USD 2.7 billion by 2030 , up from an estimated USD 1.5 billion in 2024 . This niche but pivotal segment of oncology and neurology therapeutics is drawing attention for one core reason: it rewires the way genes behave — without altering the DNA itself.

 

HDAC inhibitors don’t kill cancer cells directly. Instead, they regulate the transcriptional machinery that drives tumor growth, neurodegeneration, and even inflammatory pathways. By inhibiting histone deacetylase enzymes, these compounds restore normal acetylation levels, allowing suppressed genes — often tumor suppressors — to become active again. In simpler terms, they nudge sick cells toward healthy behavior . That’s what makes them strategically important across multiple therapeutic areas.

 

Right now, the field is most mature in oncology. Cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) were the first diseases with HDAC approvals, but new trials are targeting glioblastoma , triple-negative breast cancer , and even solid tumors with epigenetic dysregulation . There’s also growing interest in neurology : HDAC inhibition is being explored in Alzheimer’s , Parkinson’s , and fragile X syndrome , where gene expression and synaptic plasticity are central.

 

From a stakeholder angle, the market’s ecosystem is evolving:

• Biotech innovators are spearheading discovery, especially in subtypes like class I-specific or isoform-selective inhibitors.

• Big pharma is joining later-stage development via licensing or co-development deals.

• Regulators are tightening endpoints, especially around long-term tolerability and epigenetic off-target effects.

• Investors are watching Phase 2 data closely — especially from combo trials involving checkpoint inhibitors or PARP inhibitors.

 

Another major force shaping the market? The shift toward precision oncology . As companion diagnostics become more refined, researchers are stratifying patient populations by epigenetic mutations , tumor suppressor expression , or immune modulation patterns — areas where HDAC inhibitors may offer synergistic value when paired with other targeted therapies.

 

The HDAC inhibitor class still has limitations: relatively modest single-agent efficacy in solid tumors and safety profiles that can include fatigue, cytopenias , and cardiac risk. But the pipeline is maturing. New compounds are showing greater selectivity, oral bioavailability, and reduced toxicity.

 

2. Market Segmentation and Forecast Scope

The HDAC inhibitors market breaks down across four major dimensions: by drug class , by application , by route of administration , and by region . Each of these segments reflects a different strategic lens — from how the molecule works, to where it's being used, and by whom. Let’s unpack each one.

By Drug Class

The HDAC family includes several enzyme classes — and so do the drugs targeting them. Market segmentation here is mostly based on specificity and selectivity:

• Class I HDAC Inhibitors These primarily target HDAC 1, 2, 3, and 8 — often overexpressed in hematologic malignancies. Vorinostat and romidepsin fall into this group. They account for the largest market share in 2024 , driven by their role in treating CTCL and PTCL.

• Class II and Class IV HDAC Inhibitors These have a more tissue-specific expression pattern and are being tested in solid tumors and neurological disorders. They’re seeing rising R&D interest, especially in neurodegenerative disease trials.

• Pan-HDAC Inhibitors Non-selective agents like panobinostat hit multiple classes at once. While powerful, they also come with higher toxicity risks. That said, they remain critical in late-stage oncology, especially in combination regimens .

• Isoform-Specific HDAC Inhibitors Still mostly in preclinical or Phase 1, these are the most selective — and potentially safest — approaches. Some target HDAC6, linked to tubulin acetylation and neuronal signaling .

The fastest-growing group through 2030? Likely isoform-specific inhibitors, as developers race to improve safety without compromising efficacy.

By Application

This is where things get clinically differentiated. HDAC inhibitors were born in cancer research but are now branching out.

• Oncology (Hematologic and Solid Tumors ) This is still the core market, accounting for over 70% of revenue in 2024 . Approved indications include CTCL, PTCL, and multiple myeloma. Active trials are targeting breast cancer, glioblastoma, and colorectal cancer — especially in combination with immunotherapies.

• Neurology & Psychiatry Preclinical momentum is growing fast. HDAC inhibition has shown promise in reversing memory loss, improving synaptic plasticity, and modulating neuroinflammation. Indications under study include Alzheimer’s , Huntington’s , and depression — though nothing’s approved yet.

• Inflammatory and Autoimmune Disorders A smaller but promising area. Early-stage trials are investigating HDAC modulation in rheumatoid arthritis , inflammatory bowel disease , and systemic lupus erythematosus , given the role of epigenetic regulation in immune cell behavior .

Oncology will dominate in volume, but neurology could shift the narrative if even one late-stage trial crosses the finish line.

By Route of Administration

• Oral HDAC Inhibitors These are preferred for chronic dosing — especially in outpatient oncology and neuro trials. Oral delivery also supports better patient adherence. Most current market approvals are oral formulations , and that trend will likely continue.

• Injectable (IV) HDAC Inhibitors Used mostly in hospitals or infusion centers . While powerful, they are less convenient for long-term use. Some newer injectables are being paired with nanoparticle delivery to improve tolerability and tissue targeting.

By Region

• North America Largest market in 2024 due to FDA-approved therapies and robust clinical trial infrastructure. U.S. oncology guidelines include HDAC inhibitors in certain hematologic cancer protocols.

• Europe Slightly more conservative on approvals, but strong research base. The EMA has greenlit several HDAC inhibitors, especially for rare cancers. Germany and the UK are hotspots for neuroepigenetics R&D.

• Asia Pacific Fastest growth expected. China is investing heavily in epigenetic drug development, and Japan has multiple domestic biotech players developing HDAC candidates.

• Latin America, Middle East & Africa (LAMEA) Still in early adoption phase. Limited access to specialty oncology drugs and high out-of-pocket costs constrain uptake. However, Brazil and Saudi Arabia are emerging as clinical trial destinations for HDAC studies.

 

3. Market Trends and Innovation Landscape

The HDAC inhibitors space is evolving fast — not just with new molecules, but new combinations, smarter targeting, and broader disease focus. Innovation here isn’t about flashy delivery tech or viral platforms. It’s about fine-tuning how we modulate gene expression — and making it safe, repeatable, and scalable across diseases.

Let’s unpack what’s shifting.

More Precise Targeting Is Becoming the Norm

First-gen HDAC inhibitors were sledgehammers. They hit multiple enzyme classes, leading to off-target effects like fatigue, cytopenias , and ECG changes. Now, researchers are moving toward class-specific and isoform-selective inhibitors — like HDAC6 or HDAC3-specific compounds.

Why does that matter?

Because different diseases need different epigenetic tweaks . HDAC6, for instance, is key in neurodegeneration and immune regulation, but far less involved in transcriptional repression. By isolating specific HDAC isoforms, developers are aiming for:

• Lower toxicity

• Chronic dosing potential

• Better tissue specificity (e.g., brain-penetrant agents)

Startups and academic labs are driving this trend — often licensing preclinical candidates to mid-size pharma firms once they show in vivo efficacy with clean safety signals.

Combo Therapies Are Leading the Oncology Strategy

HDAC inhibitors rarely shine as monotherapies — especially in solid tumors . But they’re proving valuable when used alongside:

• Checkpoint inhibitors HDACs regulate PD-L1 expression and T-cell infiltration. Combining them with PD-1 or CTLA-4 blockers could break immune resistance in “cold” tumors .

• PARP inhibitors There’s synergy here, especially in BRCA-wild-type tumors . HDAC inhibition impairs DNA repair, enhancing the effect of PARP blockade.

• Proteasome inhibitors This combo (e.g., with bortezomib) is being used in relapsed/refractory multiple myeloma with some success — and ongoing trials in Asia are expanding indications.

Bottom line: the role of HDAC inhibitors in cancer may never be solo — but as a powerful "epigenetic primer" to unlock better responses from other therapies.

Neurology Is the Next R&D Battleground

The shift from oncology to neuro is gaining momentum — quietly but meaningfully. Several biotech firms are testing HDAC inhibitors in neurodegenerative disease models :

• Memory rescue in Alzheimer’s models (via HDAC2/HDAC6 inhibition)

• Motor function improvement in Huntington’s

• Mood regulation and resilience in chronic stress and depression

There’s even a Phase 2 trial underway in fragile X syndrome , a rare genetic disorder tied to transcriptional repression. Early animal models suggest that HDAC inhibition could restore synaptic protein expression.

The challenge? Crossing the blood–brain barrier (BBB) while maintaining selectivity. Companies are now developing brain-penetrant HDAC inhibitors , with lipophilic profiles and P-glycoprotein evasion — a major milestone if proven safe.

Epigenetic Biomarkers Are Gaining Traction

For years, HDAC inhibitor trials struggled with patient selection. Now, things are changing. Biomarkers like:

• Histone acetylation levels

• Mutations in epigenetic regulators (e.g., EZH2, ARID1A)

• Baseline PD-L1 or T-cell infiltration

…are being used to stratify patients. Some trials even use circulating tumor DNA ( ctDNA ) to track epigenetic reprogramming in real time.

One investigator recently called it “treating the epigenome like a moving target — and tracking response like we do viral load in HIV.”

This precision-guided approach may turn niche HDAC trials into scalable programs — especially if paired with AI-powered transcriptomic analysis.

AI-Driven Discovery Platforms Are Speeding Up Pipelines

Several biotech firms are using machine learning to screen novel HDAC compounds. These platforms analyze :

• Isoform selectivity

• ADME (absorption, distribution, metabolism, excretion) properties

• Toxicity signatures

Instead of screening 10,000 analogs in vitro, they’re predicting the top 20 to synthesize — cutting lead time by up to 70%.

Expect faster IND filings, more focused candidate libraries, and fewer preclinical failures over the next five years.

 

4. Competitive Intelligence and Benchmarking

The HDAC inhibitors market isn’t as crowded as checkpoint inhibitors or kinase blockers — but the competition is heating up. A handful of approved players dominate hematologic applications, while dozens of small biotechs are chasing the next generation of safer, more selective molecules. What sets the frontrunners apart isn’t just trial results — it’s how they balance regulatory risk, target selectivity, and smart partnerships.

Here’s how the competitive landscape stacks up.

Merck & Co.

Merck entered the HDAC space through its acquisition of OncoEthix , gaining access to entinostat , a class I-selective HDAC inhibitor. The molecule’s main use case is in ER-positive breast cancer , particularly in combination with hormone therapies and immuno-oncology agents. Merck is also exploring epigenetic combinations under its broader Keytruda umbrella.

Their strategy? Combine epigenetic priming with immune checkpoint dominance to improve solid tumor response rates.

Novartis

One of the early movers, Novartis markets panobinostat , approved for use in multiple myeloma . It's a pan-HDAC inhibitor — effective but relatively toxic — and is often reserved for later-line therapy in combo with proteasome inhibitors. Novartis has kept a narrow focus but remains influential in HDAC class benchmarking.

They’ve recently shifted focus toward second-generation isoform-selective HDACs , collaborating with academic groups to explore indications in glioblastoma and medulloblastoma .

Acrotech Biopharma (Aurobindo Pharma Group)

This emerging player now markets romidepsin , acquired from Celgene. Romidepsin is FDA-approved for CTCL and PTCL , giving Acrotech a foothold in hematologic cancers. The company is banking on expanding indications through investigator-led studies, especially in relapsed T-cell malignancies .

For them, it’s about maximizing commercial yield from a niche but stable approval.

Syndax Pharmaceuticals

A standout in the innovation tier, Syndax is developing entinostat in combination with exemestane for hormone receptor-positive breast cancer. The compound has shown promise in epigenetic immune modulation , with trials in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC) as well.

What’s compelling? Syndax is among the few firms with HDAC programs in both oncology and immunology — a dual path many are watching closely.

C4 Therapeutics

C4 is not a classic HDAC developer — but they’re bringing something new: HDAC-targeted protein degraders . Rather than just inhibiting enzyme activity, these molecules tag HDACs for destruction via the ubiquitin-proteasome pathway. It’s early-stage, but this “degrade rather than block” model could upend how we think about epigenetic therapy .

They’re working on a selective HDAC6 degrader , aimed at neurodegenerative disease and autoimmune indications .

Reverie Labs

A rising AI-first biotech, Reverie uses deep learning to design HDAC inhibitors with optimized isoform selectivity . Their first candidate — a brain-penetrant HDAC2/HDAC6 dual inhibitor — is entering preclinical stages for Alzheimer’s disease .

They’re a pure discovery-stage company, but their computational approach could disrupt traditional med chem timelines — especially in CNS drug design .

Other Notables

• Mirati Therapeutics had previously explored HDAC-related epigenetic combos in lung cancer but pivoted toward KRAS inhibition.

• Epizyme (now part of Ipsen) shifted toward EZH2 inhibition , another epigenetic target — showing how adjacent mechanisms are overlapping in competitive strategy.

• S*BIO , Chroma Therapeutics , and others once prominent in HDAC R&D, have largely exited or been absorbed — underscoring the volatility of this field.

 

Competitive Dynamics at a Glance:

Company	Focus	Notable Asset	Strategy
Merck & Co.	Oncology	Entinostat	Epigenetic + IO combos
Novartis	Hematology	Panobinostat	Legacy approval, R&D shift to CNS
Acrotech Biopharma	Hematology	Romidepsin	Lifecycle management
Syndax Pharma	Oncology & Immunology	Entinostat	Combo-centric approach
C4 Therapeutics	Protein Degradation	HDAC6 degrader	Next-gen mechanism
Reverie Labs	Neurology	HDAC2/6 candidate	AI-based design

 

5. Regional Landscape and Adoption Outlook

Adoption of HDAC inhibitors varies dramatically by region — not just because of approval timelines, but because of how each health system treats advanced cancer, epigenetic modulation, and emerging neuro therapies. Some countries see these drugs as core to rare disease treatment. Others still view them as experimental, especially in non-oncology settings.

Let’s walk through the current landscape.

North America

This is the largest and most mature market for HDAC inhibitors — and where most of the innovation has originated. The U.S. FDA was the first major regulator to approve HDAC drugs, including vorinostat , romidepsin , and panobinostat , specifically for hematologic cancers .

What’s driving continued leadership?

• A robust clinical trial ecosystem for rare and relapsed cancers

• Strong uptake in specialty oncology clinics

• Growing investment in epigenetic–immunotherapy combinations

• NIH-funded preclinical research into CNS applications

There’s also increasing academic interest in neurodegeneration and psychiatric applications , especially at major centers like UCSF, Harvard, and Johns Hopkins. That said, adoption beyond cancer remains limited to clinical trials.

In short: the U.S. leads in volume, approvals, and exploratory science. Canada follows suit, but more cautiously.

Europe

Europe shares similar oncology approvals but moves more slowly on neurology-focused indications. The EMA has cleared several HDAC drugs, including panobinostat and romidepsin , for rare cancers — often under conditional marketing authorization .

The region’s strength lies in academic consortia and early-stage R&D — particularly in:

• Germany and France , where HDAC research intersects with neuroepigenetics

• The UK , where HDAC inhibitors are being studied in combo trials for ovarian and breast cancer

• Scandinavia , which is exploring rare CNS indications like Rett syndrome and ALS

However, market access is a challenge. National payer systems often delay reimbursement for epigenetic drugs unless there’s strong survival or quality-of-life data. That’s made pan-EU adoption uneven .

Still, Europe is where many early-stage neuro trials are launched — especially for rare, gene-linked conditions.

Asia Pacific

This is the fastest-growing market , though still early in its clinical maturity. China, Japan, South Korea, and Australia are investing heavily in epigenetic therapeutics , with a strong mix of local innovation and Western partnerships.

China is:

• Running dozens of trials using domestically developed HDAC inhibitors

• Prioritizing rare cancer and CNS disorders through National Major New Drug Innovation Programs

• Developing pan-HDAC and isoform-selective agents in academic pharma clusters

Japan is taking a more targeted approach, especially in neurodevelopmental disorders . The country has historically favored CNS pipeline investments — and several Japanese biotechs are working on brain-penetrant HDAC inhibitors for conditions like fragile X syndrome and autism spectrum disorder .

South Korea and Australia are also hosting combination trials, mostly in solid tumors and multiple myeloma .

Across the region, government support for precision medicine is creating real white space — especially for HDAC programs with biomarker-driven strategies.

Latin America, Middle East, and Africa (LAMEA)

This is the least penetrated region , but it’s not absent. Brazil has approved select HDAC therapies under oncology pathways, while Saudi Arabia and the UAE are increasingly funding precision cancer programs within public health systems.

Barriers remain:

• High drug cost vs. budget constraints

• Limited local clinical trial infrastructure

• Fewer epigenetics-trained oncologists or neurologists

That said, academic–industry partnerships are beginning to form. For instance, a major pediatric cancer institute in São Paulo is studying HDAC inhibition in relapsed leukemia , using repurposed agents.

In Africa , access is minimal. Most HDAC drugs are not available through public formularies. If this changes, it will be through nonprofit-driven pediatric oncology programs or international trial sponsorships .

 

Regional Summary:

Region	Adoption Level	Growth Outlook	Focus Areas
North America	High	Moderate	Hematologic cancers, combo IO trials, emerging CNS
Europe	Moderate	Steady	Rare oncology, neuroepigenetics, early-stage trials
Asia Pacific	Growing Fast	High	New approvals, domestic innovation, neurodevelopment
LAMEA	Low	Emerging	Pediatric oncology, isolated hospital-led trials

 

6. End-User Dynamics and Use Case

HDAC inhibitors aren’t everyday prescriptions — they’re specialty drugs. So the real users aren’t individual physicians or clinics. They’re complex treatment ecosystems : oncology centers , academic research hospitals, specialized neurology departments, and trial sponsors. Each type of end user has a different tolerance for cost, complexity, and clinical risk.

Here’s how the market breaks down by end-user type.

Specialty Oncology Centers

These are the most significant buyers today. HDAC inhibitors are typically prescribed for relapsed or refractory hematologic cancers — meaning they’re used by clinicians managing tough cases, not frontline settings. At large cancer centers :

• Multidrug regimens are the norm (HDAC + proteasome inhibitor + dexamethasone, for instance)

• Companion diagnostics and biomarker panels help guide selection

• Pharmacovigilance teams monitor adverse events like QT prolongation or cytopenias

These centers often participate in investigator-initiated trials , helping repurpose HDACs for niche solid tumors or new combinations. They’re also key sites for post-approval observational studies.

The main barrier? Cost and toxicity — especially in publicly funded hospitals.

Academic Hospitals and Research Institutions

This group is driving the next chapter: HDACs in neurodegeneration , rare genetic disorders , and epigenetic reprogramming . Here, the end user isn’t a prescriber — it’s often a principal investigator running a Phase 1/2 trial or a translational research team working through animal models.

Their goals:

• Validate BBB-penetrant HDACs in Alzheimer’s , Rett syndrome , and ALS

• Use brain imaging + CSF biomarkers to track early efficacy

• Publish data that justifies larger pharma collaboration

These institutions also lead the effort in developing isoform-selective HDAC candidates that may reduce side effects or target new indications.

To be honest, academic centers aren’t big spenders — but they drive the science that makes future spending possible.

Biopharma Clinical Trial Sponsors

Though not “users” in the traditional sense, sponsors are the ones who shape where and how HDAC inhibitors get used next. Their role includes:

• Designing basket or umbrella trials with HDAC inhibitors across tumor types

• Co-developing companion diagnostics to enrich for likely responders

• Partnering with CROs to deploy Phase 2/3 trials globally — especially in APAC and Eastern Europe

What they care about:

• Patient adherence in oral HDAC trials

• Combination feasibility with IO or PARP drugs

• Regulatory endpoint clarity — particularly in CNS disorders

They’re a shadow stakeholder — but critical to the future of HDAC market expansion.

Specialty Pharmacies and Hospital-Based Dispensing Units

On the distribution side, HDAC inhibitors are usually routed through specialty pharmacy networks or hospital-based oncology dispensing units . These systems manage:

• Prior authorizations

• Adherence support (especially for oral agents)

• Insurance coordination for expensive combination therapies

Hospitals with dedicated oncology/ hematology wings often house internal pharmacy teams that monitor usage patterns and toxicity rates in real time.

Use Case Highlight:

A neuro-oncology center in South Korea recently enrolled pediatric glioblastoma patients in a trial for an HDAC6-selective inhibitor combined with low-dose radiation. The goal: epigenetically “soften” tumor cells to improve radiation sensitivity. Using a brain-penetrant oral formulation, the center saw encouraging signs — improved MRI response after 8 weeks, with manageable fatigue as the primary adverse event.

This isn’t just about new drugs. It’s about new strategies to make old modalities — like radiation — more effective through epigenetic reprogramming.

 

7. Recent Developments + Opportunities & Restraints

The HDAC inhibitors space has been relatively quiet compared to immunotherapies or RNA-based platforms — but don’t mistake that for stagnation. Behind the scenes, several strategic moves, new trials, and next-gen innovations are shifting the trajectory of this niche therapeutic class.

Recent Developments (2023–2025)

• Syndax Pharmaceuticals advanced its selective HDAC inhibitor entinostat into a Phase 3 trial for HR-positive, HER2-negative breast cancer , in combination with hormonal therapy. The trial, E2112, is one of the largest HDAC combination studies to date.

• C4 Therapeutics reported preclinical data on its HDAC6-targeted degrader , showing strong efficacy in multiple myeloma models with reduced cytotoxicity compared to standard HDAC inhibitors. A first-in-human trial is planned for late 2025.

• A collaboration between Harvard Medical School and Japanese biotech Eisai launched a Phase 1 trial for a brain-penetrant HDAC1/2 inhibitor targeting Alzheimer’s disease . The molecule showed improved synaptic function in rodent models and cleared early toxicity hurdles.

• Acrotech Biopharma received expanded access approval for romidepsin in select European markets, where it is being used under special-use oncology programs in relapsed peripheral T-cell lymphoma .

• Reverie Labs , using an AI-first pipeline, identified a new HDAC6/8 dual inhibitor for CNS use. The molecule is currently in IND-enabling studies for fragile X syndrome , with plans to pursue rare pediatric disease designation.

Opportunities

1. Precision Oncology Expansion With more trials using biomarkers like histone acetylation status , PD-L1 levels , or tumor immune infiltration , there’s a path to use HDAC inhibitors as a synergistic primer in immunotherapy-resistant cancers.

Opportunity Insight: These drugs may not lead treatment — but they could widen the response window for checkpoint inhibitors, especially in cold tumors .

2. CNS Therapeutics and Brain-Penetrant HDACs Multiple biotech firms are pursuing HDAC2 and HDAC6 inhibitors that cross the blood–brain barrier. If safety is established, they could become first-in-class therapies for Alzheimer’s , ALS , and cognitive impairment in schizophrenia .

3. Isoform Selectivity to Reduce Toxicity Next-gen molecules are being built with tight isoform selectivity , which may lower systemic side effects like cytopenias and fatigue — a key hurdle that’s held back broader adoption.

Restraints

1. Safety and Tolerability Profile Despite their mechanistic promise, most HDAC inhibitors have narrow therapeutic windows. Adverse events — particularly cardiac toxicity , myelosuppression , and GI side effects — still limit long-term use and dosing flexibility.

2. High Development Cost vs. Narrow Indications Developing an HDAC drug that only treats rare cancers or niche neuro conditions isn’t cheap. Without clear expansion paths or broad biomarker-validated populations, many programs struggle to justify late-phase investment .

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 1.5 Billion
Revenue Forecast in 2030	USD 2.7 Billion
Overall Growth Rate	CAGR of 8.9% (2024 – 2030)
Base Year for Estimation	2023
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Drug Class, By Application, By Route of Administration, By Geography
By Drug Class	Class I HDAC Inhibitors, Class II/IV HDAC Inhibitors, Pan-HDAC Inhibitors, Isoform-Selective Inhibitors
By Application	Oncology (Hematologic, Solid Tumors), Neurology & Psychiatry, Inflammatory & Autoimmune Disorders
By Route of Administration	Oral, Injectable (IV)
By Region	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, UK, France, Japan, China, South Korea, Brazil, India
Market Drivers	- Rising use of HDACs in combination cancer therapy - Expansion of CNS trials with brain-penetrant inhibitors - Advances in isoform-selective epigenetic targeting
Customization Option	Available upon request